These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy.
    Author: Mao K, Badoual C, Camparo P, Delongchamps NB, Vieillefond A, Dinh-Xuan AT, Peyromaure M.
    Journal: Can J Urol; 2008 Oct; 15(5):4257-62. PubMed ID: 18814815.
    Abstract:
    OBJECTIVES: To study the prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor VEGFR-1 in localized prostate cancer. METHODS: One hundred patients undergoing radical prostatectomy (RP) for clinically localized prostate cancer were prospectively included. Plasma levels of VEGF-A were measured preoperatively. After intervention, tissue microarrays were built from the RP specimens. VEGF-A and VEGFR-1 expressions in prostate cancer tissue were determined using immunochemistry. Then the associations between plasma levels of VEGF-A, VEGF-A and VEGFR-1 expressions in prostate cancer tissue, and the outcome of patients were analyzed. RESULTS: After a median follow-up of 22 months, 14 patients experienced biological recurrence of prostate cancer. There was no correlation between plasma VEGF-A and the risk of recurrence following RP. Moreover, there was no correlation between VEGF-A expression or VEGFR-1 expression in prostate cancer tissue and the risk of recurrence after RP. CONCLUSIONS: Plasma levels of VEGF-A, the expression of VEGF-A and that of VEGFR-1 in prostate cancer tissue did not affect patients outcome following RP. VEGF-A and its receptor VEGFR-1 may have no prognostic value in localized prostate cancer. Further studies with longer follow-up are mandatory to confirm these findings.
    [Abstract] [Full Text] [Related] [New Search]